36 results
8-K
LYEL
Lyell Immunopharma, Inc.
20 Nov 23
Departure of Directors or Certain Officers
4:26pm
a repriced Eligible Option before the end of the Retention Period (as defined below), such employee will be required to pay the original exercise price … with the Company through the end of a “Retention Period” that begins on the Effective Date and ends on the earliest of the following: (i) November 15, 2024; (ii
8-K
EX-99.1
sisl3
11 Sep 23
Regulation FD Disclosure
9:16am
DEF 14A
p9hj432mjk9m0kqbfw
28 Apr 22
Definitive proxy
4:11pm
10-K
xy2i0wq0
29 Mar 22
Annual report
4:20pm
10-Q
c5sh 2iel
12 Aug 21
Quarterly report
5:07pm
424B4
c0jrg8uf9plb6x
18 Jun 21
Prospectus supplement with pricing info
12:00am
S-1/A
11y1qo9ht ce9asi45
9 Jun 21
IPO registration (amended)
7:12am
S-1/A
EX-1.1
s3yjsn2mxk657v10d4
9 Jun 21
IPO registration (amended)
7:12am